
Solara Q2 FY27 Revenue Up 33% to ₹4,178 Mn, EBITDA Doubles
Solara Active Pharma Sciences reported a strong Q2 FY27, with revenue increasing by 33% year-on-year to INR 4,178 Mn and EBITDA more than doubling to INR 769 Mn. This marks the company's best quarter in five years. The base business (excluding Ibuprofen) saw revenue grow by 37% YoY to INR 3,273 Mn and EBITDA by 68% YoY to INR 771 Mn, with margins expanding by 440 bps to 23.6%. The Ibuprofen business also showed improvement, with revenue up 21% YoY to INR 905 Mn and EBITDA loss narrowing significantly to INR 2 Mn, nearing breakeven. Profit After Tax (PAT) stood at INR 285 Mn, a substantial improvement from a loss of INR 101 Mn in Q2 FY26. Net debt decreased by 19% to INR 5,000 Mn, with Net Debt to EBITDA ratio improving to approximately 1.8x.
Key Highlights
- Q2 FY27 revenue surged 33% YoY to INR 4,178 Mn.
- EBITDA more than doubled, up 118% YoY to INR 769 Mn.
- PAT turned positive at INR 285 Mn, compared to a loss last year.
- Base business revenue grew 37% YoY, Ibuprofen business nearing breakeven.
- Net debt reduced by 19% to INR 5,000 Mn.
Price Impact
More from SOLARA